TSLP, which acts upstream of IL-4/13 in the type 2 inflammation cascade, may be a promising therapeutic option for patients with CRSwNP and comorbid asthma refractory to DUP. Further studies are warranted to validate the efficacy of TEZ in the management of CRSwNP. This evidence concerns the gene IL4 and chronic rhinosinusitis with nasal polyps.